Last reviewed · How we verify
NCT02670902
Intervention for Persons Leaving Residential Substance Abuse Treatment
NA trial testing Critical Time Intervention-Residential (CTI-R) in Substance Use Disorders in 60 participants. Completed in 31 December 2020.
1 May 2020
Quick facts
| Lead sponsor | New York University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 May 2017 |
| Primary completion | 1 May 2020 |
| Estimated completion | 31 December 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Critical Time Intervention-Residential (CTI-R)
- Enhanced Usual Discharge Services-Residential
Conditions studied
- Substance Use Disorders — all drugs for Substance Use Disorders →
Sponsor
New York University
Who can join
18 and older, any sex, with Substance Use Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This research uses a multi-phase approach to adapt and implement an established intervention, Critical Time Intervention, for a new population and setting among individuals with substance use who are at risk of relapse following residential substance abuse treatment. The goals of the study are to: (PHASE 1) identify challenges and strategies of community reentry among individuals in residential substance abuse treatment and their providers and social support networks (e.g., family, friends, community members); (PHASE 2) adapt CTI for individuals in residential substance abuse treatment to prepare them for discharge and transition back into the community; and (PHASE 3) conduct a pilot study to examine the feasibility, acceptability, and preliminary outcomes of the adapted CTI compared to enhanced usual discharge planning services.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Psychosocial interventions for people with both severe mental illness and substance misuse.
Hunt GE, Siegfried N, Morley K, Brooke-Sumner C, et al · · 2019 · cited 55× · PMID 31829430 · DOI 10.1002/14651858.cd001088.pub4
Verify or expand the search:
- PubMed search for NCT02670902
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Substance Use Disorders
Currently open trials in the same condition.
- NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
- NCT07529327 — Prevent Language Delays and Disorders Among Children of Caregivers With Substance Use Disorders With Community Groups an · NA · recruiting
- NCT07281261 — tAN for Substance Use Disorder · NA · recruiting
- NCT07210268 — Temporal Interference Methods for Addiction Treatment · NA · recruiting
- NCT07146633 — Efficacy of an EMDR App for PTSD and SUD · NA · recruiting
Other New York University trials
Trials by the same sponsor.
- NCT07526246 — Motor-based Intervention for Childhood Apraxia of Speech: DTTC-Connect · NA · not yet recruiting
- NCT07519941 — Promoting Change in Practice for Respiratory Failure · NA · not yet recruiting
- NCT07071753 — Optimizing Online Purchasing of Fruits, Vegetables, and Legumes for Low-Income Families · NA · not yet recruiting
- NCT07530900 — Prediction of Visual Feedback Effects on Speech Motor Adaptation in Healthy Adults · NA · not yet recruiting
- NCT07278934 — Testing the Impact of Family-Based Intervention to Improve Developmental and Health Outcomes for Female Adolescents · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02670902 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by New York University
- Last refreshed: 1 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02670902.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing